Avantor, Inc. (NYSE:AVTR) Stock Has Consensus Price Target of $12.47

Shares of Avantor, Inc. (NYSE:AVTR) have earned a consensus recommendation of “Hold” from the eighteen research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $12.88.

Several research firms have recently weighed in on AVTR. Jefferies Financial Group upgraded Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective on the stock in a report on Wednesday, July 29th. Royal Bank Of Canada raised their target price on shares of Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Barclays lifted their price target on shares of Avantor from $13.00 to $15.00 and gave the company an “underweight” rating in a research note on Wednesday. Wolfe Research upgraded shares of Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $13.00 price objective on shares of Avantor in a research report on Thursday, July 30th.

Hedge Funds Weigh In On Avantor

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in shares of Avantor by 9.5% during the 3rd quarter. GAMMA Investing LLC now owns 51,035 shares of the company’s stock worth $768,000 after acquiring an additional 4,443 shares in the last quarter. Elevation Wealth Partners LLC lifted its position in shares of Avantor by 72.3% in the third quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock worth $42,000 after purchasing an additional 1,176 shares in the last quarter. Moody National Bank Trust Division bought a new stake in shares of Avantor in the third quarter worth $1,810,000. Versant Capital Management Inc boosted its holdings in Avantor by 56.1% during the third quarter. Versant Capital Management Inc now owns 14,163 shares of the company’s stock worth $213,000 after purchasing an additional 5,090 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in Avantor by 100.1% during the second quarter. Sequoia Financial Advisors LLC now owns 22,739 shares of the company’s stock worth $225,000 after purchasing an additional 11,378 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Avantor Price Performance

Shares of AVTR stock opened at $15.69 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. Avantor has a 12-month low of $7.26 and a 12-month high of $16.38. The firm has a fifty day moving average of $14.67 and a 200-day moving average of $11.11. The firm has a market capitalization of $10.61 billion, a price-to-earnings ratio of -18.68, a price-to-earnings-growth ratio of 11.62 and a beta of 0.94.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%. The business had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. During the same quarter last year, the business posted $0.24 EPS. The firm’s revenue was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, equities research analysts forecast that Avantor will post 0.81 earnings per share for the current year.

About Avantor

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.